U081 Hidradenitis Suppurativa and Pityriasis Rubra Pilaris: Updates on Treatments for Two Conditions that are Difficult to Manage
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
In this session participants will improve their ability to diagnose and manage patients who have hidradenitis suppurativa or pityriasis rubra pilaris, two skin conditions that are challenging to treat but have a significant impact on patient quality of life. Challenging patient cases will be shared. This session aims to update the practicing dermatologist's armamentarium for treating these two diseases. Potential new therapeutics for these diseases will also be discussed.
LEARNING OBJECTIVES
Use up-to-date information to develop appropriate treatment plans for patients with hidradenitis suppurativa.
Recognize and diagnose challenging cases of pityriasis rubra pilaris.
Select the best treatment options for patients with pityrasis rubra pilaris.
SCHEDULE
2:30 PM
Hidradenitis Suppurativa
Jennifer Lin Hsiao, MD, FAAD
2:55 PM
Pityriasis Rubra Pilaris
Scott Worswick, MD, FAAD
3:20 PM
Question and Answer
Jennifer Lin Hsiao, MD, FAAD, Scott Worswick, MD, FAAD
SPEAKERS
Jennifer Lin Hsiao, MD, FAAD
Scott Worswick, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Jennifer Lin Hsiao, MD, FAAD
AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Novartis – Consultant(Fees), Speaker(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); UCB – Consultant(Fees), Speaker(Fees);
Scott Worswick, MD, FAAD
Boehringer-Ingelheim – Advisory Board(Honoraria);